Search
Ruxolitinib
go.drugbank.com/drugs/DB08877ApprovedInvestigationalBy inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. … [A229938] Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012.
Toripalimab
go.drugbank.com/drugs/DB15043ApprovedInvestigationalThe proliferation of some cancers can be attributed, at least in part, to the suppression of host tumor surveillance. … One mechanism by which this occurs is through the overexpression of programmed cell death ligand (PD-L1)[A261506] - the binding of PD-L1 (and PD-L2) to its target receptor (PD-1) results in the inhibition
Isoeugenol
go.drugbank.com/drugs/DB14188ApprovedAllergic reactivity to Isoeugenol may be identified with a patch test. … It is also a significant dermatologic sensitizer and allergen, and as a result has been restricted to 200 p.p.m. since 1998 according to guidelines issued by the fragrance industry [A34278].
Fluoxymesterone
go.drugbank.com/drugs/DB01185ApprovedIllicitAn anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women.
Categories: Sex Hormones and Modulators of the Genital SystemDaxibotulinumtoxinA
go.drugbank.com/drugs/DB17929ApprovedInvestigational[L47865] On August 14, 2023, the drug was also approved for the treatment of cervical dystonia. … [A261075, L47860] DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines.
Etretinate
go.drugbank.com/drugs/DB00926ApprovedWithdrawnIt is thought to bind to the retinoic acid receptors. Etretinate is also believed to enhance the binding of cAMP to the regulatory RI subunit of cAMP dependent protein kinases. … Etretinate was taken off the market in Canada in 1996 and America in 1998 due to the risk of birth defects. Etretinate is now used to treat T-cell lymphomas.
Sulconazole
go.drugbank.com/drugs/DB06820Approved[L44592,L44597] Sulconazole appears to be effective and well-tolerated in the treatment of superficial fungal infections.[A255612] … Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and tinea corporis
Magnesium gluconate
go.drugbank.com/drugs/DB13749ApprovedWithdrawnAlthough magnesium is available in the form of sulphates, lactate, hydroxide, oxide and chloride, only magnesium gluconate is recommended for magnesium supplementation as it appears to be better absorbed … Magnesium is ubiquitous in the human body, and is naturally present in many foods, added to other food products, available as a dietary supplement and used as an ingredient in some medicines (such as antacids
Fexofenadine
go.drugbank.com/drugs/DB00950ApprovedInvestigational[L4269] It is selective for the H<sub>1</sub> receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier[L10779] - this is in contrast to previous first-generation … Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms.
Dexibuprofen
go.drugbank.com/drugs/DB09213ApprovedWithdrawnIt is proposed to be more pharmacologically active and tolerable with a better safety profile than ibuprofen due to higher concentration of active S enantiomer. … Dexibuprofen has a slower dissolution rate in the simulated gastric and enteric juices compared with the racemic ibuprofen and displays improved oral bioavilability [A19259].